Sanofi (Global Rights to Enjaymo) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Sanofi (Global Rights to Enjaymo) General Information

Description

A global rights to Enjaymo located in the United States. The asset consists of global rights to Enjaymo treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Corporate Office
  • United States
Primary Industry
Buildings and Property
Acquirer
Corporate Office
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sanofi (Global Rights to Enjaymo) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sanofi (Global Rights to Enjaymo)‘s full profile, request access.

Request a free trial

Sanofi (Global Rights to Enjaymo) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sanofi (Global Rights to Enjaymo)‘s full profile, request access.

Request a free trial

Sanofi (Global Rights to Enjaymo) FAQs

  • Where is Sanofi (Global Rights to Enjaymo) headquartered?

    Sanofi (Global Rights to Enjaymo) is headquartered in .

  • What industry is Sanofi (Global Rights to Enjaymo) in?

    Sanofi (Global Rights to Enjaymo)’s primary industry is Buildings and Property.

  • Is Sanofi (Global Rights to Enjaymo) a private or public company?

    Sanofi (Global Rights to Enjaymo) is a Private company.

  • What is the current valuation of Sanofi (Global Rights to Enjaymo)?

    The current valuation of Sanofi (Global Rights to Enjaymo) is .

  • What is Sanofi (Global Rights to Enjaymo)’s current revenue?

    The current revenue for Sanofi (Global Rights to Enjaymo) is .

  • Who are Sanofi (Global Rights to Enjaymo)’s investors?

    Sanofi has invested in Sanofi (Global Rights to Enjaymo).

  • When was Sanofi (Global Rights to Enjaymo) acquired?

    Sanofi (Global Rights to Enjaymo) was acquired on 29-Nov-2024.

  • Who acquired Sanofi (Global Rights to Enjaymo)?

    Sanofi (Global Rights to Enjaymo) was acquired by Recordati.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process